173 related articles for article (PubMed ID: 380803)
1. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.
Chard RL; Krivit W; Bleyer WA; Hammond D
Cancer Treat Rep; 1979; 63(11-12):1755-9. PubMed ID: 294306
[TBL] [Abstract][Full Text] [Related]
3. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
Rosenstock JG; Donaldson MH
Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
[No Abstract] [Full Text] [Related]
5. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).
Chiuten DF; Bennett JM; Creech RH; Glick J; Falkson G; Brodovsky HS; Begg CB; Muggia FM; Carbone PP
Cancer Treat Rep; 1979 Jan; 63(1):7-11. PubMed ID: 369693
[TBL] [Abstract][Full Text] [Related]
6. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
Hayes FA; Abromowitch M; Green AA
Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
[TBL] [Abstract][Full Text] [Related]
7. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group Study.
Ryan DH; Kopecky KJ; Head D; Gumbart CN; Grever MR; Karanes C; Weick JK; Coltman CA
Cancer Treat Rep; 1987; 71(7-8):713-6. PubMed ID: 3475171
[TBL] [Abstract][Full Text] [Related]
10. Teniposide: a review of 12 years of experience.
O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
[No Abstract] [Full Text] [Related]
11. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
Radice PA; Bunn PA; Ihde DC
Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
[No Abstract] [Full Text] [Related]
12. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of neocarzinostatin in children with cancer.
Rivera G; Howarth C; Aur RJ; Pratt CB
Cancer Treat Rep; 1978 Dec; 62(12):2105-7. PubMed ID: 156067
[TBL] [Abstract][Full Text] [Related]
14. [VP 16-213 in the treatment of acute leukemia in childhood].
Esumi N; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1983 Mar; 10(3):848-51. PubMed ID: 6576730
[TBL] [Abstract][Full Text] [Related]
15. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.
Rivera G; Avery T; Pratt C
Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225
[TBL] [Abstract][Full Text] [Related]
16. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of prednimustine in children with recurrent cancer: a Children's Cancer Study Group report.
Gaynon PS; Baum ES; Krivit W; Hammond D
Cancer Treat Rep; 1982 Jul; 66(7):1583-4. PubMed ID: 6284362
[No Abstract] [Full Text] [Related]
18. Phase I clinical evaluation of diaziquone in childhood cancer.
Ettinger LJ; Siegel SE; Belasco JB; Evans AE; Ruccione KS; Jamin DC; Rohrbaugh TM; Higgins GR
Cancer Treat Rep; 1985 Mar; 69(3):323-7. PubMed ID: 3856480
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of NK 171 (etoposide) on malignant lymphomas and acute leukemia. A cooperative study group on NK 171 in hematological malignancies].
Kimura K; Yamada K; Yoshida T
Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):496-501. PubMed ID: 3954373
[TBL] [Abstract][Full Text] [Related]
20. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment.
Rodriguez V; McCredie KB; Keating MJ; Valdivieso M; Bodey GP; Freireich EJ
Cancer Treat Rep; 1978 Apr; 62(4):493-7. PubMed ID: 350386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
